Jun 10, 2020 in Diagnostics, Press Releases

Diagnostic Partner 3a Receives BMBF Grant for Infectious Disease Screening Tests

Vancouver, Canada (June 10, 2020) – XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC:XPHYF) (“XPhyto” or the “Company”) is pleased to announce that its diagnostic partner, 3aDiagnostics GmbH (“3a”) and their contract research collaborators, have received a €254,200 grant from the German Federal Ministry of Education and Research (“BMBF”). The BMBF grant is part of the “KMU-innovativ” program for small and medium-sized enterprises that are pioneering innovation and technological progress in Germany. Proceeds of the grant are committed to the development and commercialization of enzyme activated biosensors for use in real-time, lowcost and easy-to-use oral screening tests for the rapid detection of influenza A virus and specific variants that are high-risk pandemic threats such as H1N1 and H5N1.

XPhyto and 3a signed a definitive development, technology purchase and licence agreement, announced April 20, 2020, for the incorporation of 3a’s pathogen-specific biosensors into XPhyto’s dissolvable thin film (“ODF”) platform. Development work is underway and a program update will be announced in due course.

3a is a research-based biotechnology company located approximately 50 kilometers Southeast of Stuttgart, Germany, specializing in the development, production and marketing of point-ofcare test systems. 3a refers to their approach as “anywhere” (no power or additional equipment required), “anytime” (decentralized and rapidly deployable), and “anyone” (no specialized training required).

“We are very pleased to receive the support and validation from BMBF for our infectious disease test development program,” said Dr. Heinrich Jehle, Managing Director of 3a. “We believe that low cost, distributable and decentralized screening tests will be a critical component of global population-scale pandemic management.”

Media Inquiries
E: info@bionxt.com